Capmatinib launch date in China

Capmatinib (Capmatinib) belongs to the tyrosine kinase inhibitor (TKI) class. It was developed by Novartis Pharmaceuticals and was approved for medical use in the United States in May 2020. It is the first therapy approved by the U.S. Food and Drug Administration (FDA) to treat non-small cell lung cancer with specific mutations (mutations that cause mesenchymal-to-epithelial transition or MET exon 14 skipping). The original drug of capmatinib has not yet been launched in China, and the specific launch is unclear. Capmatinib is also currently in the clinical trial stage for other tumors. Patients who need this drug can currently only purchase it through overseas channels.